Brain et al. [8] reported an incidence for FN of 40.8% in a breast cancer study using doxorubicin 50 mg/m2/docetaxel 75 mg/m2 and suggested to use primary G-CSF prophylaxis for this regimen. The gene discussed is CSF3; the disease is breast carcinoma.